A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured signal to daydream about weekend plans. We have a busy agenda this time around. We plan to hang with some of our short people. We will also provide a rare, guided tour of the Pharmalot ancestral grounds, since only we know where the bodies are buried. Let us know if you would like to join us. Space is limited. And what about you? You could grab your calculator and divine the impact of the looming tax bill or changes that may appear in your cable bill at some point. You could willfully ignore these developments and plan a holiday getaway. Or stand outside and hope to look past the horizon. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Two months after a Gilead Sciences (GILD) drug was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, while others linger on waiting lists, Bloomberg News reports. Five people have received the treatment, called Yescarta, at the 15 cancer hospitals authorized to administer it in the U.S., and waiting lists for the $373,000 treatment have grown to at least 200 people.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.